Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 10/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297142 | 0.84 | DRD2 (0.48) | DRD2KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL15289811 | 0.84 | DRD2 (0.48) | DRD2KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL9885074 | 0.78 | KMT2A (0.54) | DRD2KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL5542830 | 0.78 | KMT2A (0.54) | DRD2KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL22054525 | 0.77 | HPGD (0.53) | KMT2AKDM4E | |
| SCHEMBL3942686 | 0.76 | KMT2A (0.56) | DRD2KMT2AACACBCKS1BSKP1 | |
| SCHEMBL4377073 | 0.76 | KMT2A (0.56) | DRD2KMT2AACACBCKS1BSKP1 | |
| SCHEMBL190838 | 0.76 | KMT2A (0.56) | DRD2KMT2AACACBCKS1BSKP1 | |
| SCHEMBL3816616 | 0.76 | KMT2A (0.56) | DRD2KMT2AACACBCKS1BSKP1 | |
| SCHEMBL24120720 | 0.74 | ALDH1A1 (0.42) | DRD2KMT2ASMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | DRD2 3803/4885KMT2A 2730/4885SMN1; SMN2 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.